We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

86 hedge funds and large institutions have $473M invested in UroGen Pharma in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 40 increasing their positions, 24 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 24

36% more capital invested

Capital invested by funds: $347M → $473M (+$126M)

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

2% more funds holding

Funds holding: 84 → 86 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less call options, than puts

Call options by funds: $8.04M | Put options by funds: $8.55M

2.09% less ownership

Funds ownership: 69.69% → 67.6% (-2.1%)

Holders
86
Holders Change
+2
Holders Change %
+2.38%
% of All Funds
1.69%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
10
Increased
40
Reduced
24
Closed
8
Calls
$8.04M
Puts
$8.55M
Net Calls
-$511K
Net Calls Change
+$119K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.48M
2
PF
Phoenix Financial
Israel
+$4.2M
3
JP Morgan Chase
JP Morgan Chase
New York
+$3.41M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$3.28M
5
WCM
Wildcat Capital Management
New York
+$2.72M

Top Sellers

Rank Fund Capital Flow
1
CI
Clal Insurance
Israel
-$14M
2
SFM
Sphera Funds Management
Israel
-$8M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.47M
4
PM
Prosight Management
Texas
-$2.94M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$2.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
Zurich Cantonal Bank
76
Zurich Cantonal Bank
Switzerland
$43K -$31.1K -1,139 -47%
AIM
77
Aigen Investment Management
New York
$41K +$33.5K +1,228 New
Public Employees Retirement Association of Colorado
78
Public Employees Retirement Association of Colorado
Colorado
$37K – – –
HCA
79
Horan Capital Advisors
Ohio
$33K – – –
TRCT
80
Tower Research Capital (TRC)
New York
$20K -$38.3K -1,404 -70%
First Manhattan
81
First Manhattan
New York
$16K – – –
MAM
82
Meeder Asset Management
Ohio
$10K +$5.62K +206 +210%
LC
83
Lindbrook Capital
California
$9K +$7.37K +270 New
US Bancorp
84
US Bancorp
Minnesota
$5K +$300 +11 +8%
Daiwa Securities Group
85
Daiwa Securities Group
Japan
$3K -$409 -15 -11%
SPIA
86
Steward Partners Investment Advisory
New York
$3K – – –
SFM
87
Sphera Funds Management
Israel
– -$8M -335,817 Closed
SAM
88
Sectoral Asset Management
Quebec, Canada
– -$1.55M -65,063 Closed
N
89
Nuveen
North Carolina
– -$1.08M -45,444 Closed
ARTA
90
A.R.T. Advisors
New York
– -$338K -14,203 Closed
Millennium Management
91
Millennium Management
New York
– -$258K -10,855 Closed
Squarepoint
92
Squarepoint
New York
– -$221K -9,289 Closed
QT
93
Quantamental Technologies
New York
– -$81K -3,400 Closed
1 2 3
4

URGN Hedge Fund Activity: Q4 2019 in Review

86 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2019, worth a combined $473M — up 36% from $347M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new URGN positions and 8 closed out — a net gain of 2 holders — while 40 added to existing stakes and 24 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $4.48M. The largest seller was Clal Insurance, cutting an estimated $14M.

  • 86 institutional investors held UroGen Pharma (URGN) as of Q4 2019, up from 84 in Q3 2019.
  • Funds reported $473M of UroGen Pharma stock for Q4 2019, up 36% quarter-over-quarter.
  • 10 funds opened new UroGen Pharma positions in Q4 2019 and 8 closed out, a net change of +2 holders.
  • The largest UroGen Pharma buyer in Q4 2019 was Point72 Asset Management, an estimated $4.48M added.
  • The largest UroGen Pharma seller in Q4 2019 was Clal Insurance, an estimated $14M sold.

Based on aggregated 13F filings for Q4 2019.